HealthEquity (HQY) Guidance Reset Sparks Sell-Off—Is the New Baseline Sustainable?

The market's reaction to HealthEquity's fourth-quarter report hinges on a classic expectation gap. The numbers themselves tell a mixed story. The company posted a diluted EPS of $0.58, which missed the consensus estimate of $0.91 by a significant margin. Revenue, at $334.6 million, came in just slightly ahead of the $336.4 million estimate. So, the print was a miss on earnings per share but a beat on top-line sales.

This creates a familiar dynamic. Over the last four quarters, HealthEquity has surpassed consensus EPS estimates four times. The pattern has been one of consistent "beat and raise" momentum, where strong results often lead to higher guidance and a stock price that climbs on the rumor. The expectation for this quarter, therefore, was likely already priced for another positive surprise. When the actual EPS came in well below that elevated benchmark, it triggered a "sell the news" reaction. The market had baked in a beat; the reality was a miss, however the revenue beat provided some offsetting relief.

The bottom line is that the whisper number for EPS was high, and the company didn't meet it. That gap between the priced-in optimism and the actual print is what drove the stock's underperformance, despite the underlying business showing strong profitability and cash flow.

The Guidance Reset: A New Baseline

Management's raised outlook for fiscal 2027 is the clear catalyst here, attempting to reset the market's trajectory after the EPS miss. The guidance numbers are substantial: a projected net income of $239M–$246M. On the surface, that implies a growth rate of 10-13% from the record fiscal 2026 net income of $215.2 million. That's a solid, if not spectacular, step forward.

The critical expectation gap, however, is between this new baseline and the path the market had been pricing in. Analysts had been projecting a 26.8% EPS growth rate for fiscal 2026 based on the prior year's performance. The raised guidance for next year, therefore, represents a significant deceleration from that recent high-growth trajectory. In essence, management is setting a new, lower expectation floor. The stock's underperformance may be a direct result of this guidance reset, as the market absorbs the reality that the blistering growth phase is likely over for now.

Yet, the operational foundation remains strong. The company ended the year with record HSA assets of $36.5 billion, up 14% year-over-year, and added a million new HSAs from sales for the second straight year. This growth provides the fuel for the guided expansion. The guidance also includes a robust Adjusted EBITDA outlook of $618M–$628M, reflecting continued operating leverage.

So, does this guidance justify the recent sell-off? The answer depends on what you value. For investors chasing hyper-growth, the reset is a disappointment. For those focused on a more sustainable, cash-generative model, the guidance provides a clearer, albeit slower, path. The key is that the market's priced-in optimism for another year of 25%+ EPS acceleration has been replaced with a new, more conservative baseline. The stock's job now is to prove that this new floor is solid.

Valuation and the Forward Look

The market is now weighing the improved guidance against a stock that has been under pressure for months. HealthEquity shares are down 14.56% year-to-date, a decline that has persisted even as the company's operational metrics remain strong. This sets up a clear tension: the stock trades at a steep discount to its narrative fair value, yet it is also priced for a growth trajectory that management's own raised guidance now suggests may be slowing.

Wall Street sentiment remains bullish on paper, with an 87.5% Buy/Strong Buy consensus. But the recent price target cuts tell a different story. Analysts like Barclays, BTIG, and Goldman Sachs have trimmed their targets in recent weeks, with Goldman's downgrade to Sell highlighting a growing wariness. This divergence between ratings and price targets is a classic sign of an expectation gap. The ratings reflect confidence in the long-term HSA platform story, while the price cuts signal that the near-term path to profitability is being scrutinized more harshly.

The key watchpoint for closing this gap is the upcoming earnings call. Management must validate the raised guidance with concrete evidence. The market is demanding proof that account growth and custodial asset trends can support the company's stated goal of a 30% EPS growth trajectory into fiscal 2027. If the call shows reacceleration in these core metrics, it could reignite the "buy the rumor" momentum. If not, the guidance reset may prove to be the start of a longer period of consolidation.

The bottom line is that the expectation gap has not fully closed. The stock's recent decline suggests the market is skeptical of the new, slower growth baseline. For the stock to rally, HealthEquity must not only meet the raised guidance but also demonstrate that the underlying engine of account and asset growth is still powerful enough to justify a return to higher growth rates. Until then, the valuation story will remain a tug-of-war between a discounted price and a reset growth story.